12 May 2020 – Posting of Annual Report and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]

Audited results for the year ended 31 December 2019 and clinical development update

Link to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]

Clinical and Business Update

Link to Full Article Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address […]

Update on the development of XF drug formulations

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]

Destiny Pharma appoints Dr Debra Barker as Non-Executive Director

Link to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]

Positive results published from an independent (US National Institute of Health) XF-73 phase 1 clinical trial in a peer reviewed journal

Link to Full Article The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of […]

Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye  Marks the fourth research grant Destiny […]

Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye  Marks the fourth research grant Destiny […]

Destiny Pharma appoints NOMAD and Joint Broker

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of NOMAD and Joint Broker Brighton, United Kingdom – 9 May 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces the appointment of finnCap Ltd as Nominated […]

Audited results for the year ended 31 December 2018

Link to Full Report Well-funded and on track Brighton, United Kingdom – 9 April 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces its audited financial results for the year ended 31 December 2018. Financial […]